{"schema_version":"secwatch.filing_event.v1","accession":"0001650664-24-000111","form_type":"8-K","ticker":"EDIT","cik":"0001650664","company_name":"Editas Medicine, Inc.","filed_at":"2024-10-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.108535+00:00","generated_at":"2026-05-30T20:20:10.526471+00:00","sec_items":["1.01","2.03","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Editas Medicine monetizes Vertex license fees for $57M upfront from DRI Healthcare Trust","bullets":["Upfront cash payment of $57M from DRI subsidiary for up to 100% of future annual license fees ($5M-$40M/year) and a mid-double-digit % of $50M contingent payment under Vertex Cas9 license.","Non-dilutive capital to fund pipeline development and strategic priorities; Editas retains 2024 fixed fees and a mid-single-digit million milestone payment from Vertex.","Purchase agreement has no financial covenants; potential liquidated damages or termination fees of one-to-two times the upfront payment under specified conditions.","Vertex license (Dec 2023) covers Cas9 technology for ex vivo BCL11A gene editing in sickle cell disease and beta thalassemia, including CASGEVY."],"urls":{"canonical":"https://secwatch.observer/filing/0001650664-24-000111","json":"https://secwatch.observer/filing/0001650664-24-000111.json","markdown":"https://secwatch.observer/filing/0001650664-24-000111.md","text":"https://secwatch.observer/filing/0001650664-24-000111.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1650664/000165066424000111/0001650664-24-000111-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1650664/000165066424000111/edit-20241003.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T20:20:10.526471+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}